Frusemide infusion for the prevention of deterioration in renal function post cardiac surgery.

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000386639

Enrollment

400

Registered

2005-09-14

Start date

2002-11-20

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

The frusemide infusion group- which will be monitored to achieve a trial specified hourly urine output target range of 1-2 ml/kg/hr. In order to achieve this target the patients may need to receive a loading dose of frusemide and may also require a frusemide infusion. The aim will be to maintain the urine output within the target range for the first 48 hours after cardiac surgery.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Prevention

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

All patients admitted for cardiac surgery will be assessed for eligibility. Participants will be approached for inclusion from the pre-admission clinics, and wards of the Cardiothoracic surgery unit. Potential participants will be identified by daily review of planned cardiothoracic surgery schedules. Prior to inclusion in this study permission to approach patients will be obtained from involved treating Intensivists and Surgeons.

Exclusion criteria

Patients will be excluded if:1.already in established dialysis dependent chronic renal failure.2.known allergy to frusemide. 3.age < 184.Pregnant.

Outcome results